Fulgent Genetics (FLGT) Change in Accured Expenses (2015 - 2026)

Fulgent Genetics has reported Change in Accured Expenses for 12 years, with the latest figure at -$11.9 million in Q2 2026.

• Quarterly Change in Accured Expenses fell 328.64% year-over-year to -$11.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$2.8 million (up 18.82% YoY) and the FY2025 annual result came in at $8.9 million, up 324.97% from the prior year.
• Change in Accured Expenses eased to -$11.9 million in Q2 2026 per FLGT's latest filing, from -$2.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $12.3 million in Q4 2025 and troughed at -$13.2 million in Q3 2022.
• A 5-year average of -$959222.2 and a median of -$654500.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses plunged 932.2% in 2024, then soared 1862.58% in 2025.
• Over 5 years, Change in Accured Expenses stood at $2.0 million in 2022, then jumped by 423.32% to $10.4 million in 2023, then tumbled by 93.97% to $628000.0 in 2024, then jumped by 1862.58% to $12.3 million in 2025, then sank by 196.52% to -$11.9 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$11.9 million, -$2.1 million, and $12.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.